State of Alaska Department of Revenue boosted its position in Pfizer Inc. (NYSE:PFE) by 70.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,238,419 shares of the biopharmaceutical company’s stock after purchasing an additional 512,311 shares during the quarter. Pfizer comprises approximately 1.1% of State of Alaska Department of Revenue’s investment portfolio, making the stock its 6th largest position. State of Alaska Department of Revenue’s holdings in Pfizer were worth $44,854,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Heritage Way Advisors LLC grew its holdings in Pfizer by 103.6% in the 4th quarter. Heritage Way Advisors LLC now owns 109,902 shares of the biopharmaceutical company’s stock valued at $3,981,000 after buying an additional 55,926 shares in the last quarter. BKD Wealth Advisors LLC grew its holdings in Pfizer by 3.4% in the 4th quarter. BKD Wealth Advisors LLC now owns 103,664 shares of the biopharmaceutical company’s stock valued at $3,755,000 after buying an additional 3,451 shares in the last quarter. WealthTrust Arizona LLC grew its holdings in Pfizer by 146.7% in the 4th quarter. WealthTrust Arizona LLC now owns 19,708 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 11,720 shares in the last quarter. Community Financial Services Group LLC grew its holdings in Pfizer by 0.6% in the 4th quarter. Community Financial Services Group LLC now owns 216,884 shares of the biopharmaceutical company’s stock valued at $7,856,000 after buying an additional 1,375 shares in the last quarter. Finally, Westpac Banking Corp grew its holdings in Pfizer by 4.6% in the 4th quarter. Westpac Banking Corp now owns 639,100 shares of the biopharmaceutical company’s stock valued at $23,148,000 after buying an additional 28,036 shares in the last quarter. 71.16% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Charles H. Hill sold 42,393 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Insiders have sold a total of 248,037 shares of company stock valued at $9,064,785 over the last 90 days. 0.06% of the stock is currently owned by company insiders.
Pfizer Inc. (NYSE:PFE) opened at $36.33 on Tuesday. Pfizer Inc. has a twelve month low of $31.67 and a twelve month high of $39.43. The company has a market capitalization of $218,946.36, a PE ratio of 13.88, a P/E/G ratio of 2.07 and a beta of 0.91. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The company had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same period last year, the business posted $0.47 EPS. Pfizer’s revenue for the quarter was up .6% on a year-over-year basis. equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer declared that its Board of Directors has approved a share repurchase plan on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://weekherald.com/2018/03/20/pfizer-inc-pfe-is-state-of-alaska-department-of-revenues-6th-largest-position.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.